Breaking News

Tweet TWEET

Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference

  Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap   Conference  Bank of America Merrill Lynch Smid Cap Conference 2014  Business Wire  LOS ANGELES -- March 12, 2014  Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:45 a.m. EDT on Wednesday, March 19, at the Bank of America Merrill Lynch 2014 Smid Cap Conference. The conference will be held at The Ritz-Carlton, Boston Common.  A live webcast will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.  About Puma Biotechnology  Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation.  Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.  Forward-Looking Statements:  This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.  Contact:  Puma Biotechnology, Inc. Alan H. Auerbach or Mariann Ohanesian, +1 424-248-6500 info@pumabiotechnology.com ir@pumabiotechnology.com or Russo Partners Andreas Marathovouniotis or David Schull, +1 212-845-4235 andreas.marathis@russopartnersllc.com david.schull@russopartnersllc.com  
Press spacebar to pause and continue. Press esc to stop.